Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Craig W. Hendrix, Kristine B. Patterson, Namandjé N. Bumpus et al.|AIDS Research and Human Retroviruses|2015Cited by 177
Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender menEugenie Shieh, Craig W. Hendrix|Journal of the International AIDS Society|2019Cited by 80
Differential Requirements for Actin Polymerization, Calmodulin, and Ca<sup>2+</sup>Define Distinct Stages of Lysosome/Phagosome TargetingWalter Stockinger, Axel Nohturfft, Shao C. Zhang et al.|Molecular Biology of the Cell|2006Cited by 48
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Namandjé N. Bumpus, Craig W. Hendrix, Vanessa Elharrar et al.|UNC Libraries|2020Cited by 0